Proceedings at the annual general meeting of TopoTarget A/S


To the Copenhagen Stock Exchange
Announcement No. 09-07 / Copenhagen, 12 April 2007
 

Proceedings at the annual general meeting of TopoTarget A/S

The company's annual general meeting was held on Wednesday, 11 April 2007, as
per the notice convening the meeting dated 27 March 2007. 

Note was taken of the Chairman's and the CEO's reports and the financial
statements for 2006 were unanimously adopted by the shareholders at the general
meeting. 

The Board of Directors' proposal to carry the loss for the year of DKK 106.2
million forward to next year was unanimously adopted. 

The proposal by the Board of Directors to authorise the acquisition of treasury
shares by the Board was unanimously adopted. 

Also, the Board of Directors' proposal to authorise the Board to issue up to a
total of 1,000,000 warrants, each entitling the holder to subscribe for one
share of DKK 1 nominal value, and to make the relevant capital increases, was
unanimously adopted. The authorisation will be included as a new article 6a in
the company's articles of association and is expected to be registered with the
Danish Commerce and Companies Agency as soon as possible. 

All members of TopoTarget's Board of Directors were re-elected.

Deloitte was re-appointed as TopoTarget's auditors.

TopoTarget A/S


For further information, please contact:

Dr. Peter Buhl Jensen		Telephone	 +45 39 17 83 41
Chief Executive Officer		Mobile	 +45 21 60 89 22

Leif Hamø			         Telephone	 +45 39 17 83 45
Chief Financial Officer		Mobile	 +45 40 33 40 83









Background information

About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company,
headquartered in Denmark and with subsidiaries in the UK, Germany and the USA,
dedicated to finding ''Answers for Cancer'' and developing improved cancer
therapies. TopoTarget is founded and run by clinical cancer specialists and
combines years of hands-on clinical experience with in-depth understanding of
the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer enzyme regula-tors (mainly HDAC, mTOR, and topoisomerase
II inhibitors) and a strong development foundation has been built. TopoTarget
has a broad portfolio of small molecule preclini-cal drug candidates and seven
drugs are in clinical development, including both novel anti-cancer
therapeutics and new cancer indications for existing drugs. Savene™ is
TopoTarget's first product on the market. In addition to organic growth,
TopoTarget consistently looks for opportunities to strengthen and expand its
activities through acquisitions and in-licensing. For more information, please
refer to Hwww.topotarget.com.H 


TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline includ-ing the timing for commencement and completion of clinical
trials and with respect to cash burn guidance.  Such statements are based on
management's current expecta-tions and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, 
the following: the risk that any one or more of the drug development programs
of TopoTarget will not proceed as planned for technical, scientific or
commercial reasons or due to patient enrolment issues or based on new
information from nonclinical or clinical studies or from other sources; the
success of competing products and technolo-gies; technological uncertainty and
product development risks;  uncertainty of addi-tional funding; TopoTarget's
history of incurring losses and the uncertainty of achieving profitability;
TopoTarget's stage of development as a biopharmaceutical company; government
regulation; patent infringement claims against TopoTarget's products, processes
and technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.

Attachments

announcement no. 09 07 proceedings at agm 12 april 2007.pdf